Fly News Breaks for September 13, 2017
Sep 13, 2017 | 07:43 EDT
After Sage's Brexanolone drug missed the primary and secondary endpoints of its Phase 3 trial involving Super-Refractory Status Epilepticus, or SRSE, patients, Needham analyst Danielle Brill says the results do not impact her view of the drug's efficacy in post-partum depression, or PPD,. She says that PPD is much easier to treat than SRSE, while the drug;s mechanism of action is different in PPD versus SRSE. The analyst notes that the drug demonstrated that it lowered PPD by statistically significant amounts in a previous trial. She cut her price target on the stock to $86 from $95 but keeps a Buy rating on the shares.
News For SAGE From the Last 2 Days
There are no results for your query SAGE